A new study has added to data suggesting that HDL cholesterol (HDL-c) – sometimes called ‘good’ cholesterol, as it can help protect against heart disease – may be a risk f
NewAmsterdam Pharma's bold play to resurrect an all-but defunct cholesterol-lowering drug class has been rewarded with a positive phase 2 trial of its oral CETP inhibitor obicetrapib.